Update to “Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors”

This letter to the editor reports subsequent rechallenge with peptide receptor radionuclide therapy (PRRT) in a patient with pancreatic neuroendocrine tumor bearing BRCA1 mutation previously treated with PRRT.

Detalles Bibliográficos
Autores principales: Zhu, Mojun, Bekaii-Saab, Tanios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177096/
https://www.ncbi.nlm.nih.gov/pubmed/35403684
http://dx.doi.org/10.1093/oncolo/oyac068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177096/
https://www.ncbi.nlm.nih.gov/pubmed/35403684
http://dx.doi.org/10.1093/oncolo/oyac068

Ejemplares similares